Madrigal Pharmaceuticals (MDGL) Other Accumulated Expenses (2010 - 2016)

Madrigal Pharmaceuticals (MDGL) has 7 years of Other Accumulated Expenses data on file, last reported at $1.4 million in Q2 2016.

• Other Accumulated Expenses for Q2 2016 came in at $1.4 million, up 27.08% year-over-year; the trailing twelve-month figure through Jun 2016 was $1.4 million (up 27.08% YoY), and the FY2015 annual result was $5.0 million, up 378.46% from the prior year.
• Other Accumulated Expenses fell to $1.4 million in Q2 2016 per MDGL's latest filing, from $2.8 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $5.7 million in Q4 2013 and troughed at $609000.0 in Q1 2013.
• A 5-year average of $2.7 million and a median of $2.0 million in 2012 frame the typical range for Other Accumulated Expenses.
• On a YoY basis, Other Accumulated Expenses climbed as much as 567.35% in 2014 and fell as far as 81.81% in 2014.
• A 5-year view of Other Accumulated Expenses shows it stood at $5.1 million in 2012, then advanced by 11.53% to $5.7 million in 2013, then plunged by 81.81% to $1.0 million in 2014, then surged by 378.46% to $5.0 million in 2015, then slumped by 70.86% to $1.4 million in 2016.
• Business Quant data shows MDGL's Other Accumulated Expenses at $1.4 million in Q2 2016, $2.8 million in Q1 2016, and $5.0 million in Q4 2015.